Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.

Slides:



Advertisements
Similar presentations
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Advertisements

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
CLINICAL CHARACTERISTICS AND OUTCOMES FOR BENIGN AND MALIGNANT SOLITARY FIBROUS TUMOR / HEMANGIOPERICYTOMA (SFT/HPC) – A SINGLE CENTER EXPERIENCE Nicholas.
Multi trial evaluation of longitudinal tumor measurement (TM)-based metrics for predicting overall survival (OS) using the RECIST 1.1 data warehouse Background:
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
Casulo C et al. Proc ASH 2013;Abstract 510.
How to get more nodes in laparoscopic colon surgery John Marks MD Chief Division of Colorectal Surgery Lankenau Hospital and Institute of Medical Research.
SHELBY ADDISON NEAL, MD MENTORS: WILLIAM T. CREASMAN, MD WHITNEY S. GRAYBILL, MD, MS Lymph-Vascular Space Invasion (LVSI) in Uterine Corpus Cancer What.
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
PROGNOSTIC SIGNIFICANCE OF PRIMARY TUMORAL FDG UPTAKE MEASURED BY PET: Systematic Review and Meta-analysis Ben A. Dwamena, MD.
Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
A Propensity-matched Study of Lobectomy Versus Segmentectomy for Radiologically Pure Solid Small-sized Non-small Cell Lung Cancer Terumoto Koike 1, Seijiro.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.
Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
Kerrington Smith, M.D. CTOS Nov 14, 2008
Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;
S L I D E 0 Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Christopher D. Corso MD PhD, Shane.
Lymphadenectomy in Epithelial Ovarian Cancer
Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.
A Quantitative Multi-Gene RT-PCR Assay for Prediction of Recurrence in Stage II Colon Cancer (CC): Selection of the Genes in 4 Large Studies and Results.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
An Assessment of Factors Affecting Outcome in Patients Presenting with Metastatic Soft Tissue Sarcoma Peter Ferguson MD1,2, Benjamin Deheshi MD1,2, Anthony.
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
Investigation of CA9 expression in pulmonary metastatic lesions from patients with clear cell renal cell carcinoma Pierre Tennstedt 1, Peter Schneider.
Age, SexHistologyPredominant subtype Pathological stage EGFR mutation CAF1 61, MaleAdenocarcinoma Solid predominant pT3N2M0 L858R CAF2 71, MaleAdenocarcinoma.
Supplementary table 1 Supplementary table 1. Clinical-pathological features of the resection-only and chemotherapy/resection stage II/III colorectal cancer.
Outcomes Following Adjuvant 5-FU based Treatment (AT) for Colon Cancer vs Impact on Recurrence Rate, Time from Recurrence to Death.
Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results.
“Validation” of the Proposed IASLC/ITMIG Staging Revisions of Thymic Carcinomas Using Data from 287 Patients Yang Zhao; Heng Zhao Division of Thoracic.
Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
on behalf of the ACOSOG Z4032 Investigators
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.
CHFR METHYLATION AS AN EPIGENETIC MARKER FOR RECURRENCE OF COLON CANCER M. D. Anderson Cancer Center, Houston, Texas Motofumi Tanaka, Salil Sethi, Donghui.
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
Adjuvant Radiation is Not Associated with Improved Survival in Patients with Positive Margins Following Lobectomy for Stage I & II Non-Small Cell Lung.
Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.
Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.
14 th Annual Meeting of the Connective Tissue Oncology Society November 13-15, 2008, London, UK Oliver Zivanovic, Mario M. Leitao, Alexia Iasonos, Lindsay.
Lymph Node (LN) Ratio (LNR) Based Risk Classification (RC) in Stage III Colon Cancer (CC) with Internal and External Validation: Finding from the ACCENT.
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.
Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. Ugwuji N. Maduekwe, Francis J. Hornicek, Dempsey S.
Results Abstract Analysis of Prognostic Web-based Models for Stage II and III Colon Cancer: A Population-based Validation of Numeracy and Adjuvant! Online.
Discussant Slides: Title: Radiosensitivity Index Shows Promise for Predicting Outcomes with Adjuvant Radiation in Resected Pancreatic Cancer Patients Poster.
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
Association of Family History with Cancer Recurrence and Survival in Patients with Gastric Cancer Journal of Clinical Oncology : R2 Hwang.
COMPARING DISEASE OUTCOME OF WOMEN WITH HORMONE RECEPTOR NEGATIVE/HER2 POSITIVE (HR-/HER2+) OR TRIPLE NEGATIVE (TN) METASTATIC BREAST CANCER (MBC) RECEIVING.
Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;
Prognostic significance of tumor subtypes in male breast cancer:
R. Michelle Sarin, MD Mentor: Jeffrey Fowler, MD
Aspirin Associated With Reduced Mortality in Patients With CRC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
Lung squamous cell carcinoma
Brain imaging prior to lung cancer resection
Prognosis of younger patients in non-small cell lung cancer
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL.
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Treated with Neoadjuvant Therapy
GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR
Supplementary Figure S1
Presentation transcript:

Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence for clinical variables such as age, stage, smoking status, and LN involvement as clinical prognostic factors in pulmonary carcinoids. A prognostic calculator incorporating Ki-67 and clinical variables is under development. Conclusions Pulmonary carcinoid tumors [typical carcinoid (TC) and atypical carcinoid (AC)] account for up to 5% of all lung cancers and for unclear reasons they have shown the greatest increase in incidence from 1973 to 2004 according to the SEER database. TC is commonly indolent and well differentiated, while AC is usually highly aggressive and poorly differentiated. The evaluation of the prognostic factors and biomarkers of carcinoid tumors of the lung is limited due to the rarity of the disease. This study assessed Ki-67 expression and other clinical variables as prognostic factors in 262 patients. Background WHO Criteria Results Tumor Tracing Technique & Imaging Analysis of Ki-67 Expression A Ki-67 proliferation index cutoff value of 1% accurately predicts 5-year RFS and OS in patients with pulmonary carcinoid tumors Reungwetwattana T. 1, 2, Mandrekar SJ. 1, Kroneman TN. 1, Foster NR. 1, Aubry MC. 1, Yi JE. 1, Kerr SE. 1, Yang P. 1, Grothey A. 1, Shridhar V. 1, Voss JS. 1, Kipp BR. 1, Molina JR. 1 1 Mayo Clinic, Rochester, MN, USA, 2 Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Median follow-up on alive-patients is 5 years (range: ). Age, stage, smoking history, lymph node (LN) involvement and Ki-67 index were significant prognostic factors in RFS and OS for pulmonary carcinoids. Tumor with the longest dimension of > 2 cm had significant worse RFS compared with the smaller tumor size (≤ 2 cm) with HR of 2.03 (95% CI; 1.14, 3.63 and P = 0.014). Gender, presenting symptoms, location of tumor, type of surgery, number of resected LN, status of tumorlets, and status of multicentric foci were not significant prognostic factors. Objectives To study the impact of Ki-67 expression (proliferative index) and the other clinical variables as the prognostic factors of pulmonary carcinoids on survival outcomes (RFS and OS). Methods A systematic search of Mayo Clinic lung cancer epidemiology and tumor registry databases from 1997 to 2009 identified 449 consecutive patients, with 262 having available tissue blocks [40 atypical carcinoids (AC) and 222 typical carcinoids (TC)]. Clinical data were collected by chart review. Tissue blocks were centrally reviewed by 1 of 3 pathologists according to WHO criteria. With respect to the original diagnosis, 19 AC patients were revised to TC, and 13 TC patients were revised to AC. Statistical analyses were performed based on the original and revised diagnosis. Tumors were tested for the Ki-67 index using digital image analysis (tumor tracing) by two operators in half of the specimen. The concordance between two operators was observed then the rest of specimens were performed by one operator. The association and predictive value of the factors with recurrence-free and overall survival (RFS and OS) were explored using univariable Cox proportional Hazards model and concordance (c) index. Abstract ID: Pathological Features Typical carcinoid Atypical carcinoid Organoid pattern Yes Mitoses < 2/2 mm /2 mm 2 Necroses None+/- Nuclear/cytoplasmic ratio Moderate NucleoliOccasionalCommon Nuclear chromatinFinely granular Correlation Curve Between Two Operators for Ki-67 Analysis Outcomes RFSOS HR; 95% CI (P-value) C-indexHR; 95% CI (P-value) C-index Ki-67 ≥ 1% vs. < 1% 3.69; (<0.0001) ; (0.0007) 0.66 AC vs. TC (original diagnosis) 3.85; (<0.0001) ; (0.0214) 0.59 AC vs. TC (central-reviewed diagnosis) 4.24; (<0.0001) ; (0.0007) 0.64 VariableNDeaths OS Log- rank P-value OS Hazard Ratio (95% CI) RFS Events RFS Log-rank P-value RFS Hazard Ratio (95% CI) Age <= 50) (0.35,6.99) (0.53,4.44) (0.92,12.13) (1.31,8.23) > (1.25,16.00) (1.30,8.50) Staging < I II (0.70,7.37) (0.90,5.22) III (1.78,12.84) (2.12,9.33) IV (2.65,23.67) (3.57,19.46) Smoking Status Never Smokers Former Smokers (0.97,5.48) (0.87,3.07) Current Smokers (1.39,10.01) (1.21,5.52) Status of Metastatic LN < Negative Positive (2.32,13.55) (2.53,8.91) Univariable Cox PH Model for RFS and OS Table: Pulmonary Carcinoids Categorized by Ki-67 at cut point of 1% % Ki-67 by operator # 1 % Ki-67 by operator # 2